Aldeyra Therapeutics, Inc. (ALDX) Raised to Sell at ValuEngine
ValuEngine upgraded shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) from a strong sell rating to a sell rating in a report issued on Tuesday.
Several other equities research analysts have also issued reports on ALDX. Zacks Investment Research upgraded shares of Aldeyra Therapeutics from a hold rating to a buy rating and set a $4.75 price target on the stock in a research note on Thursday, August 10th. Stifel Nicolaus reiterated a buy rating and issued a $16.00 price target on shares of Aldeyra Therapeutics in a research note on Wednesday, May 31st. Canaccord Genuity set a $12.00 price target on shares of Aldeyra Therapeutics and gave the company a buy rating in a research note on Wednesday, June 14th. Finally, HC Wainwright set a $18.00 price target on shares of Aldeyra Therapeutics and gave the company a buy rating in a research note on Thursday, June 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The company has an average rating of Buy and an average price target of $15.95.
Aldeyra Therapeutics (ALDX) opened at 9.6555 on Tuesday. The stock’s 50 day moving average is $4.62 and its 200 day moving average is $4.72. Aldeyra Therapeutics has a 12-month low of $3.80 and a 12-month high of $11.05. The stock’s market capitalization is $60.30 million.
Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.02. Analysts forecast that Aldeyra Therapeutics will post ($1.63) EPS for the current year.
In other Aldeyra Therapeutics news, major shareholder Life Sciences Maste Perceptive purchased 296,007 shares of the stock in a transaction on Friday, June 30th. The shares were purchased at an average cost of $4.60 per share, for a total transaction of $1,361,632.20. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 28.40% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Sphera Funds Management LTD. grew its position in shares of Aldeyra Therapeutics by 81.4% in the 1st quarter. Sphera Funds Management LTD. now owns 668,500 shares of the biotechnology company’s stock valued at $3,343,000 after acquiring an additional 300,000 shares during the period. Sabby Management LLC bought a new position in shares of Aldeyra Therapeutics in the 1st quarter valued at about $898,000. Perceptive Advisors LLC grew its position in shares of Aldeyra Therapeutics by 48.7% in the 1st quarter. Perceptive Advisors LLC now owns 2,885,458 shares of the biotechnology company’s stock valued at $12,897,000 after acquiring an additional 945,000 shares during the period. Virtu KCG Holdings LLC bought a new position in shares of Aldeyra Therapeutics in the 2nd quarter valued at about $104,000. Finally, Vanguard Group Inc. grew its position in shares of Aldeyra Therapeutics by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after acquiring an additional 9,407 shares during the period. 49.09% of the stock is owned by institutional investors.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.